Table 1 Cox regression analysis of CENPF protein expression and clinicopathological covariates with survivals in the Cohort I.

CENPF-high vs. CENPF-low

6.242 (3.790–10.281)

5.282 (3.162–8.822)

2.347 (1.372–4.016)

2.074 (1.192–3.607)

0.010

Age (≥60 vs. < 60)

1.617 (0.959–2.724)

1.125 (0.647–1.955)

Sex (male vs. female)

0.933 (0.570–1.528)

0.797 (0.463–1.371)

Location (rectum vs colon)

1.292 (0.806–2.071)

0.714 (0.411–1.241)

TNM stage (III + IV vs I + II)

4.731 (2.829–7.911)

3.192 (1.818–5.605)

3.483 (1.992–6.091)

2.050 (1.097–3.832)

0.025

Differentiation grade (poorly vs others)

2.102 (1.213–3.640)

1.260 (0.678–2.344)

2.325 (1.282–4.218)

1.094 (0.555–2.156)

0.795

Adjuvant chemotherapy (yes vs no)

1.912 (1.104–3.310)

1.130 (0.635–2.012)

0.698 (0.409–1.192)

Lymphovascular invasion (yes vs no)

1.887 (1.031–3.456)

0.793 (0.406–1.547)

2.779 (1.512–5.109)

1.446 (0.732–2.860)

0.289

Perineural invasion (yes vs no)

2.461 (1.319–4.592)

1.770 (0.866–3.618)

2.514 (1.264–4.998)

1.942 (0.864–4.366)

0.108

Tumor size (cm) (≥4 vs <4)

1.319 (0.819–2.124)

2.172 (1.262–3.738)

2.046 (1.156–3.621)

0.014

Serum CEA (ng/ml) (≥5 vs <5)

1.651 (1.029–2.649)

1.158 (0.683–1.965)

2.206 (1.290–3.774)

1.317 (0.725–2.392)

0.366

Serum CA199 (U/ml) (≥37 vs <37)

2.024 (1.118–3.663)

1.553 (0.808–2.988)

3.382 (1.884–6.069)

2.141 (1.118–4.099)

0.022